Smell and taste function in childhood cancer patients: a feasibility study

Mirjam van den Brink 1,2 · Irene IJpma 2 · Britt van Belkom 1 · Marta Fiocco 2,3,4 · Remco C. Havermans 1 · Wim J. E. Tissing 2,5

Received: 8 May 2020 / Accepted: 22 July 2020 / Published online: 2 August 2020
© The Author(s) 2020

Abstract

Purpose Chemotherapy can affect smell and taste function. This has never been investigated in childhood cancer patients during chemotherapy. The objective of this study was to determine whether psychophysical smell and taste tests are suitable for children with cancer. Taste and smell function, fungiform papillae density, and eating behavior were measured before (T1) and after (T2) a cycle of chemotherapy and compared with healthy controls.

Methods Thirty-one childhood cancer patients treated for a hematological, solid, or brain malignancy (median age 12 years, 16 girls), and 24 healthy controls (median age: 11 years, 10 girls) participated. Smell function was measured using Sniffin’ Sticks, including a threshold, discrimination, and identification test. Taste Strips were used to determine recognition thresholds for sweet, sour, salty, and bitter taste. Papillae density was investigated by counting the fungiform papillae of the anterior tongue. Eating behavior was assessed using the Behavioral Pediatrics Feeding Assessment Scale (BPFAS).

Results Smell and taste function could be investigated in more than 90% of the patients, while fungiform papillae density could be determined in 61% of the patients. A significant difference in smell threshold was found between patients and controls ($p = 0.001$), showing lower thresholds in patients. In patients, sweet taste ($p < 0.001$), bitter taste ($p = 0.028$), and total taste function ($p = 0.004$) were significantly different after a cycle of chemotherapy, with higher scores at T2.

Conclusion The assessment of smell, taste, and fungiform papillae density is feasible in children with cancer. Results of the current study suggest that smell and taste sensitivity increased in children with cancer.

Keywords Smell · Taste · Childhood cancer · Chemotherapy

Introduction

Childhood cancer survival rates have markedly improved in recent decades [1]. Increased survival can be attributed to providing more intensive therapies. However, as a result, almost all such children suffer from bothersome or severe treatment-related side effects [2]. Nausea, vomiting, and loss of appetite are well-known side effects among childhood cancer patients, interfering with food intake [3]. Taste changes have been found to be the third most common bothersome symptom (prevalence 60.3%) [2]. These changes are an often overlooked side effect contributing to inadequate food intake, which in turn affects nutritional status [4]. Poor nutritional status in children with cancer is associated with increased infections, poor survival, and impaired health-related quality of life [5, 6].

Studies investigating changes in smell and taste among childhood cancer patients are rare. Skolin and colleagues
found that children with cancer undergoing chemotherapy had significant lower scores for bitter taste and made more taste recognition errors compared with controls [7]. However, this cross-sectional study was heterogeneous regarding chemotherapy (i.e., patients receiving doxorubicin, methotrexate, ifosfamide, cytarabine, procarbazine, dacarbazine, cisplatin, or cyclophosphamide per protocol depending on diagnosis and treatment phase), and only ten patients (median age 14.5 years) underwent a taste test. Qualitative studies indicated that changes in taste were the predominant cause of eating problems and altered food preferences in children with cancer, although specific food choices were highly variable [7, 8]. Changes in taste are often accompanied by changes in smell function. This has been found in adult patients undergoing various chemotherapy regimens (e.g., anthracycline, taxane, platinum containing) but has not been studied in childhood cancer patients during chemotherapy [9]. Only one study evaluated both smell and taste function in pediatric patients (n = 10) after bone marrow transplantation, but not during chemotherapy [10]. As current evidence comes from small studies and lack the assessment of smell function in childhood cancer patients during chemotherapy, prospective studies are needed to measure smell and taste function in children with cancer during chemotherapy.

Before investigating smell and taste changes in childhood cancer patients extensively, it must be considered whether psychophysical smell and taste assessments can be obtained without unpleasant side effects. For example, if children with cancer are rather sensitive to odors, which are regularly seen in adult patients, they might experience nausea when certain odors are presented [11]. Therefore, this study aimed to examine whether measurements of smell, taste, and fungiform papillae density are feasible (i.e., completed by more than 60% of the patients) in children with cancer and if those tests require adjustments. Furthermore, smell and taste function, fungiform papillae density, and eating behavior were evaluated during chemotherapy (i.e., before and after a cycle) and compared with healthy controls, results of which contribute to a burgeoning understanding of smell and taste changes and their consequences in children with cancer.

Patients were compared to healthy controls, matched by age and gender. Controls were recruited among siblings and friends of the patients. Participants were eligible for participation if they were between 6 and 18 years and able to understand Dutch. Exclusion criteria were as follows: isolated congenital anosmia (ICA) or a self-reported allergy to quinine.

Procedure and feasibility assessment

Patients were measured twice whereas controls were measured only once. A measurement was postponed in the case of severe oral mucositis or having a cold. During the first measurement in patients (T1), which was performed at day one of a cycle of chemotherapy somewhere during treatment protocol, feasibility of the tests was assessed. A test was considered feasible if at least 60% of the patients could complete the test without unpleasant side effects. Additionally, patients were asked to rate the tests by using smileys regarding the following topics: fun, difficulty level, concentration, and time duration.

If the first measurement in patients was considered viable, a second measurement (T2) was performed to assess potential changes in smell and taste within a cycle of chemotherapy. When a patient was admitted to the hospital for at least 4 days, the second measurement was taken on the last day of admission. In case of a shorter hospital stay, the second measurement was performed on the first day of the following chemotherapy cycle (usually 21 days later).

Measurements

Smell function

Sniffin’ Sticks (Burghart, Wedel, Germany) were used to determine smell function [12]. This test comprises three parts: odor threshold (THR), discrimination (DIS), and identification (ID). All odorants are presented in pen-like odor dispensing devices, which are positioned 2 cm in front of the patient’s nostrils for approximately 3 sec. For the THR-test, a modified set of eight dilutions of phenyl ethyl alcohol (PEA; rose-like smell) was used [13]. Each time, three pens, of which one contained PEA and two contained a non-odorous solvent, were presented to the blindfolded participant. The participant had to distinguish the odor-containing pen in a staircase up-down procedure by starting with the lowest concentration of PEA. Reversal of the staircase was triggered by two correct or one false identification until seven reversals were obtained or until five reversals if attentiveness waned. The average of the last four reversal points was used as threshold score and ranged between 1 and 15. For the DIS-test, 16 triplets, containing two equal odorants and one different odorant, were presented in a randomized order. Participants, who were blindfolded, had to determine which pen smelled differently. ID was assessed by presenting sixteen common odorants, and

Methods

Participants

This study was performed at the Princess Máxima Center for Pediatric Oncology in Utrecht, the Netherlands. Eligible patients were children diagnosed with a hematological, solid, or brain malignancy, currently treated with chemotherapy. Treatment regimens supplied during the study period can be found in Table 1.
participants had to identify these odorants by using a four-
choice task. For DIS and ID, a correct response resulted in
one point and scores range between 0 and 16.

Taste function

Filter-paper strips (Taste Strips, Burghart, Wedel, Germany) with
impregnated concentrations of sweet, sour, salty, and bitter were
used to determine taste recognition thresholds [14]. Each time,
one of four concentrations of sweet taste (0.05, 0.1, 0.2, and 0.4 g/
ml sucrose), sour taste (0.05, 0.09, 0.165, and 0.3 g/ml citric acid),
salty taste (0.016, 0.04, 0.1, and 0.25 g/ml sodium chloride), or
bitter taste (0.0004, 0.0009, 0.0024, and 0.006 g/ml quinine
hydrochloride) was presented in an order of increasing concen-
trations. Before the test began, the highest concentration of each
taste was given to familiarize participants with the taste qualities.
Taste strips were placed on the middle of the tongue for whole-
mouth testing. Participants were then asked whether the per-
ceived taste was sweet, sour, salty, bitter, or tasteless. Scores for
each taste quality range from 0 to 4, and the total taste score was
derived by summing the scores of each taste quality (range 0–16).

Subjective smell, taste, and appetite

Participants were asked to self-assess their smell, taste, and
appetite on a 5-point Likert scale (1 “very bad” to 5 “very

| Characteristics                           | Patients (n = 31) | Controls (n = 24) | p value |
|------------------------------------------|------------------|------------------|---------|
| Gender, female (n, %)                    | 16 (51.6)        | 10 (41.7)        | 0.464   |
| Age (median, range)                      | 12 (7–17)        | 11 (6–18)        | 0.658   |
| 6–8 years (n, %)                         | 7 (22.6)         | 5 (20.8)         |         |
| 9–14 years (n, %)                        | 14 (45.2)        | 13 (54.2)        |         |
| 15–18 years (n, %)                       | 10 (32.2)        | 6 (25.0)         |         |
| Diagnosis                                |                  |                  |         |
| Hematologic malignancy (n, %)            | 16 (51.6)        |                  |         |
| ALL                                      | 8 (25.8)         |                  |         |
| AML                                      | 1 (3.2)          |                  |         |
| Lymphoma                                 | 7 (22.6)         |                  |         |
| Brain tumor (n, %)                       | 3 (9.7)          |                  |         |
| Medulloblastoma                           | 3 (9.7)          |                  |         |
| Solid tumor (n, %)                       | 12 (38.7)        |                  |         |
| Bone                                     | 9 (29.0)         |                  |         |
| Rhabdomyosarcoma                         | 3 (9.7)          |                  |         |
| Chemotherapy regimen (n, %)              |                  |                  |         |
| Alkylating agents\(^a\)                  | 14 (53.8)        |                  |         |
| Anthracyclines\(^b\)                     | 7 (26.9)         |                  |         |
| Platinum agents\(^c\)                    | 4 (15.4)         |                  |         |
| Vinca alkaloids\(^d\)                    | 15 (57.7)        |                  |         |
| Antimetabolites\(^e\)                    | 11 (42.3)        |                  |         |
| Epipodophyllotoxins\(^f\)                | 5 (19.2)         |                  |         |
| Other\(^g\)                              | 11 (42.3)        |                  |         |
| Intensity of Treatment Rating (ITR)      |                  |                  |         |
| Moderate intensive (n, %)                | 11 (35.5)        |                  |         |
| Very intensive (n, %)                    | 17 (54.8)        |                  |         |
| Most intensive (n, %)                    | 3 (9.7)          |                  |         |

\(^a\) Provided chemotherapy between T1 and T2, n = 26
\(^b\) Cyclophosphamide, dacarbazine, ifosfamide, lomustine
\(^c\) Doxorubicin
\(^d\) Carboplatin, cisplatin
\(^e\) Vincristine
\(^f\) Methotrexate, 6-mercaptopurine
\(^g\) Etoposide
\(^h\) Asparaginase, dactinomycin, dexamethasone, prednisone

ALL acute lymphoblastic leukemia, AML acute myeloid leukemia
good”). In addition, participants rated their smell, taste, and appetite (1 “much worse” to 5 “much better”) compared with the start of chemotherapy (patients) or with the last month (controls).

**Fungiform papillae density**

Fungiform papillae density was investigated by staining the tongue with a 0.9% Brilliant Blue food dye (Pomona Aroma, Hedel, the Netherlands), diluted to a concentration of 1:10 at which fungiform papillae remain pink [15]. Participants were asked to extend their tongue and secure it gently between their teeth and lips. Subsequently, the tongue was dried with filter paper, stained with blue food dye, and dried again. Then, a 15-mm-diameter Whatman circular filter paper Grade 1 (GE Healthcare Life Science, Chalfont St. Giles, UK) with a 6-mm-diameter circular cut-out (area 0.283 cm²) was placed on the anterior of the left side of the tongue, next to the midline [16]. At least three close-up images of the tongue were taken by a digital camera (Canon Powershot SX70 HS, Tokyo, Japan). Afterwards, the clearest image was further investigated in Fiji, a distribution of ImageJ software (National Institutes of Health, Bethesda, USA) [17]. The Denver Papillae Protocol (DPP) was used for counting fungiform papillae [18].

**Eating behavior**

Eating behavior was assessed using the Behavioral Pediatrics Feeding Assessment Scale (BPFAS) [19]. The BPFAS is a 35-item parent-report questionnaire that consists of 25 items that focus on the child’s eating behavior and 10 items that focus on parents’ feeding strategies. For each statement, parents reported how often the particular behavior occurred on a 5-point Likert scale (1 “never” to 5 “always”). They were also asked to indicate whether they believed that this behavior was problematic or not. Four scores are thus generated: Child Behavior-Frequency (CBF) and Parent Behavior-Frequency (PBF) (which refer to how often the specific child and parent behavior occur) and Child Behavior-Problems (CBP) and Parent Behavior-Problems (PBP) (which reflect the number of behaviors seen as problematic). Higher scores indicate more eating/feeding problems [20].

**Treatment intensity**

Treatment intensity was rated with the Intensity of Treatment Rating scale (ITR-3), a psychometrically valid classification of pediatric cancer treatment, into one of four levels ranging from 1 “minimally invasive” (e.g., in case of stage 1 Wilm’s tumor) to 4 “most invasive” (e.g., in case of a brain tumor with treatment requiring HSCT) [21].

**Statistical analysis**

Descriptive statistics are presented as median with interquartile range (IQR) or number of participants (N) with percentage (%) for both groups. The Mann-Whitney U Test was used to compare smell, taste, fungiform papillae density, and BPFAS scores between controls and patients at T1. The Wilcoxon signed-rank test was used to compare changes in smell, taste, and fungiform papillae density between the two measurements. Spearman’s test was employed to investigate correlations between taste function and fungiform papillae density and taste function and eating behavior in patients at T1. A 5% alpha level was used. Data analysis was performed with IBM SPSS Statistics (version 25.0).

**Results**

**Participant characteristics**

Thirty-one patients and 24 healthy controls were included in this study (Table 1). After the first measurement, five patients left the study because they completed their treatment (n = 2), continued treatment somewhere else (n = 1), or became too ill (n = 2). Median time interval between T1 and T2 was 21 days (IQR 14–37). Six patients underwent the second measurement more than 37 days later due to postponed admissions or severe complications.

**Feasibility assessment in patients**

Twenty-nine patients (94%) performed the THR-test, and for the 23 of them (79%), a THR-score could be obtained after seven reversals of the staircase. For the remaining six patients, the THR-score was calculated after five reversals of the staircase as their attentiveness waned. For DIS and ID, 28 (90%) and 30 (97%) patients could complete these tests, respectively. Thirty patients (97%) finished the taste test. One DIS-test and taste test were prematurely terminated due to nausea. For papillae density, six patients (19%) did not undergo the measurement. Reasons for not participating in this test were as follows: nausea/gagging (n = 2), anxiety/tension (n = 2), or logistical reasons (n = 2). From the remaining 25 patients, six photos were of insufficient quality to count the fungiform papillae. Overall, fungiform papillae density could be calculated for 19 (61%) of the patients.

Concerning patients’ experiences, 81% reported that they really liked the overall assessment and 84% reported that they did not experience any problems concerning concentration. Difficulty of the tests was qualified by 71% of the patients as “a bit difficult.” In addition, 39% of the patients reported time of the assessment as “long lasting.”
Smell and taste function

Figure 1 shows smell function of the childhood cancer patients and controls. A significant difference in smell threshold was found between patients and controls ($p = 0.001$), showing lower thresholds in patients. DIS and ID were not significantly different between the two groups. In patients, no significant differences in smell function were found between the two measurements.

Compared with controls, patients had a different sour taste threshold ($p = 0.042$) (Fig. 2). Regarding the other taste qualities, no significant differences were found between patients and controls. In patients, sweet taste ($p < 0.001$), bitter taste ($p = 0.028$), and total taste function ($p = 0.004$) were significantly different after a cycle of chemotherapy, showing higher scores at T2.

Table 2 shows subjective smell, taste, and appetite of childhood cancer patients at T1. Twelve patients (39%) reported changes in smell, and 11 patients (36%) reported taste changes, reflecting both increased and decreased perceptions. In addition, 24 patients (77%) reported alterations in appetite.

Fungiform papillae density

Fungiform papillae density was neither significantly different between patients and controls, nor between the two measurements in patients (Table 3). Fungiform papillae density was not significantly correlated with taste function in children with cancer.

Eating behavior

No significant differences were found in BPFAS scores and the prevalence of eating disorders between patients and controls (Table 4). In patients, the total taste function at T1 was negatively correlated with PBF ($r = -0.402$, $p = 0.042$), meaning that a better taste function is associated with less frequently reported “poor” feeding strategies. Additionally, a difference in taste function (T1 vs T2; i.e., increased sensitivity in this case) was positively correlated with CBF ($r = 0.469$, $p = 0.037$). Thus, increased taste function in children with cancer was associated with eating disorders.
The present study has shown that assessing smell, taste, and fungiform papillae density is feasible in children with cancer, as more than 60% of the patients were able to complete the tests. Although feasible, some adaptations are deemed necessary regarding time duration and difficulty level of the tests. Furthermore, we showed that taste function increased in childhood cancer patients during chemotherapy, especially for sweet and bitter taste. Lower smell thresholds were found in patients compared with healthy controls, which suggest that both smell and taste sensitivity increased in children with cancer.

Regarding smell function, a wide step method was used for the threshold test to enhance concentration and reduce time of investigation. This method has never been used in children but has been shown reliable in adults [13]. Due to the size of our control group, and its distribution across different age categories, it was not possible to compare the threshold scores with those derived from a regularly used narrow step method [22].
Still, the wide step method provides an advantage for threshold testing in participants where time of investigation should be kept as short as possible [13]. Although only one discrimination test was prematurely terminated due to nausea, several patients noted that they did not like the intensity and large number of odorants either. Concerning odor identification, children were often not familiar with some of the odorants (e.g., turpentine, apple) from the odor identification test. This finding is consistent with a study among German children [23]. The Universal Sniff Test, a recently developed international odor identification test for children, will be more suitable as odorants are selected on familiarity [24]. This test is now commercially available, including normative values for children aged 6–17 years [22].

As smell thresholds are less influenced by age, contribute to a large extent to the diagnosis of smell loss, and seem affected the most in our study population, the assessment of smell function in children with cancer should include at least an odor threshold test [25, 26]. However, the assessment of several components of smell function, instead of a single component, is preferred. Therefore, a suitable odor identification task for children, such as the Universal Sniff Test, should be added. Odor discrimination does not seem to have much added value in children with cancer, and child-friendly tasks are lacking. Removing this task will save at least 10 min.

Investigating taste function and papillae density can be considered feasible, although the assessment of papillae density was more problematic in children with cancer. The main obstacle was not the measurement, which relatively few children disliked, but rather obtaining a proper photograph of the tongue. Photographs regularly failed due to movement of the tongue or being taken in poorly lit rooms. Sometimes, fungiform papillae were invisible because of a white layer on the surface of the tongue. The so-called oral thrush, or oral candidiasis, is common among people with a weakened immune system [27]. In addition, papillae density was not significantly different between the groups nor correlated with taste function in patients. Although feasible, the limitations and current results do not warrant further investigation of fungiform papillae density in children with cancer. Practical issues need to be overcome first to reduce the burden on children with cancer.

### Table 2
Subjective smell, taste, and appetite among childhood cancer patients at T1 ($n = 31$).

| Rating      | Number of patients (%) | Changes since start chemotherapy | Number of patients (%) |
|-------------|------------------------|----------------------------------|------------------------|
| **Smell**   |                        |                                  |                        |
| Very good   | 8 (25.8)               | Much better                      | 2 (6.4)                |
| Good        | 19 (61.3)              | Better                           | 6 (19.4)               |
| Moderate    | 4 (12.9)               | Unchanged                        | 19 (61.3)              |
| Bad         | 0 (0.0)                | Worse                            | 4 (12.9)               |
| Very bad    | 0 (0.0)                | Much worse                       | 0 (0.0)                |
| **Taste**   |                        |                                  |                        |
| Very good   | 6 (19.4)               | Much better                      | 1 (3.2)                |
| Good        | 20 (64.5)              | Better                           | 4 (12.9)               |
| Moderate    | 3 (9.7)                | Unchanged                        | 20 (64.5)              |
| Bad         | 2 (6.4)                | Worse                            | 6 (19.4)               |
| Very bad    | 0 (0.0)                | Much worse                       | 0 (0.0)                |
| **Appetite**|                       |                                  |                        |
| Very good   | 8 (25.8)               | Much better                      | 0 (0.0)                |
| Good        | 12 (38.7)              | Better                           | 11 (35.5)              |
| Moderate    | 6 (19.4)               | Unchanged                        | 7 (22.6)               |
| Bad         | 3 (9.7)                | Worse                            | 10 (32.2)              |
| Very bad    | 2 (6.4)                | Much worse                       | 3 (9.7)                |

### Table 3
Median scores (IQR) of fungiform papillae in childhood cancer patients and healthy controls.

|                     | Controls ($n = 17$) | Patients (T1) ($n = 19$) | Patients (T2) ($n = 18$) | $p$ value* |
|---------------------|---------------------|--------------------------|--------------------------|------------|
| Number of papillae  | 15.0 (12.5–24.0)    | 20.0 (15.0–28.0)         | 20.5 (17.8–25.8)         | 0.327      |
| Papillae density (cm²) | 53.1 (44.2–84.9) | 70.7 (53.1–99.0)         | 72.5 (62.8–91.1)         | 0.294      |

*IQR* interquartile range

*$p$ value between T1 and T2 within patients*
Results of our study seem to indicate that smell function sensitizes in children with cancer, showing lower smell thresholds compared with controls. Smell function did not change significantly after a cycle of chemotherapy in patients. Our findings are in contrast with those of previous studies who examined adults receiving chemotherapy. For example, women undergoing chemotherapy for breast cancer or gynecological malignancies showed increased smell thresholds during chemotherapy for testicular cancer showed no changes in smell function [28]. Although there was no measurement before diagnosis, and it cannot be ruled out that lower smell thresholds were already present before diagnosis, several children with cancer (n = 8) reported a better or much better smell perception since the start of chemotherapy. This may well be an underestimation. Increased smell sensitivity was typically judged as negative. Possibly, some children conflated their evaluation of their altered sense of smell with their altered smell sensitivity leading them to rate their sense of smell as “worse” after chemotherapy. Future research on subjective smell and taste sensitivity in children with cancer requires more careful instruction and phrasing of questions.

The current study showed increased sweet, bitter, and total taste function after a cycle of chemotherapy. So far, evidence regarding smell and taste function in childhood cancer patients during chemotherapy is limited to cross-sectional studies with small sizes. Those studies generally show reduced taste perception for all taste qualities, or bitter taste only, in children with cancer compared with healthy controls [7, 29]. When reviewing prospective studies among adults receiving chemotherapy, changes in sweet taste and, to a lesser extent, bitter taste seem more common than changes in salt or sour perception [30]. However, taste changes in the current subset of childhood cancer patients were characterized by increased perception of sweet and bitter taste, while adults generally experience a decreased perception of these taste qualities during chemotherapy. Maybe other pathways are involved in children compared with adults.

The etiology of smell and taste changes during chemotherapy is not fully understood. In general, damage to sensory receptor cells and abnormal neuronal activity are thought to be the major cause of these distortions [31]. Smell and taste receptor cells have high turnover rates, as do cancer cells, and particularly rapidly dividing cells are affected by chemotherapy. With respect to specific chemotherapeutic substances, drugs such as methotrexate, vincristine, cisplatin, carboplatin, doxorubicin, cyclophosphamide, 6-mercaptapurine, and 5-fluorouracil all seem to be associated with taste changes in adults but not necessarily with smell changes [32]. Taste changes may be also related to oral mucositis, poor oral hygiene, infections, or a dry mouth. In addition, it is presume that cancer-related inflammation can trigger apoptosis of the taste bud cells through cytokine signaling pathways, thereby contributing to the development of taste disorders [33]. An enhanced ability to smell during chemotherapy, potentially resulting in food aversions and nausea, might be a strengthened defense mechanism of the sensory organ to avoid ingestion of potentially harmful substances into the body [34]. However, many questions remain regarding smell and taste changes during chemotherapy.

Taste function was correlated with eating behavior and feeding strategies in children with cancer. This is in line with qualitative studies that already highlighted the influence of taste changes on food preferences and eating behavior [7, 8, 35]. Since eating behavior and food preferences are still developing in children, and are strongly influenced by the chemical senses, it is suggested that the impact of smell and taste changes in the long term could be large as well [36, 37]. To prevent children with cancer from inadequate food intake and bad dietary habits due to this phenomenon, longitudinal studies are needed to identify the course of smell and taste changes and its consequences regarding food intake and eating behavior during and after chemotherapy.

This study aimed to investigate feasibility of smell, taste, and papillae density assessment in children with cancer. Therefore, the current results regarding smell and

| Table 4 | Comparisons of BPFAS scores across childhood cancer patients and healthy controls |
|---------|---------------------------------|---------------------------------|---------|---------------------------------|---------------------------------|
|         | Patients (n = 26)               | Controls (n = 20)               |
|         | Median (IQR)                    | N disorder (%)                  | Median (IQR) | N disorder (%)                  |
| Child Behavior-Frequency (CBF) | 43.0 (38.5–47.3) | 3 (11.5) | 37.0 (34.3–45.8) | 2 (10.0) |
| Child Behavior-Problem (CBP)   | 0.0 (0.0–0.8)a | 3 (12.5) | 0.0 (0.0–0.0)b | 0 (0.0) |
| Parent Behavior-Frequency (PBF)| 16.0 (13.0–18.0) | 3 (11.5) | 14.0 (12.0–16.0) | 0 (0.0) |
| Parent Behavior-Problem (PBP)  | 0.0 (0.0–0.0)a | 3 (12.5) | 0.0 (0.0–0.0)b | 1 (5.9) |

IQR interquartile range

a n = 24
b n = 17
taste function do not allow for strong conclusions and should be considered tentative. Even if it is the largest study to date, the size of the current study is small, lacks a measurement at diagnosis, and varies in time intervals between measurements. Nevertheless, the prospective study design and control group make the results of this feasibility study already useful for a burgeoning understanding of smell and taste changes in children with cancer during chemotherapy.

In conclusion, the assessment of smell and taste function and fungiform papillae density is feasible in children with cancer. Future longitudinal studies should focus on smell (threshold and identification) and taste function in children with cancer, whereas the assessment of fungiform papillae density should be omitted. In addition, results of the current study suggest a remarkable increased smell and taste sensitivity in children with cancer, which was an unexpected finding and requires further investigation.

Acknowledgments The authors wish to thank all the children and their parents for participating in this study.

Code availability Not applicable.

Authors’ contributions Mirjam van den Brink participated in study design, collected data, conducted statistical analysis, and drafted the manuscript. Irene Upma participated in study design and interpretation of the data and helped to draft the manuscript. Britt van Belkom collected data. Marta Fiocco participated in statistical analysis, interpretation of the data, critical revision, and editing of the manuscript. Remco Havermans participated in study design, supervised its execution, helped with interpretation of the data, and helped to draft the manuscript. Wim Tissing participated in study design, supervised its execution, helped with interpretation of the data, and helped to draft the manuscript. All authors read and approved the final manuscript.

Funding information The Laboratory of Behavioural Gastronomy is supported by the Dutch Province of Limburg.

Date availability Data that support the findings of this study are available from the corresponding author upon reasonable request.

Compliance with ethical standards

Conflict of interest The authors declared that they have no conflict of interest.

Ethics approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Medical Ethics Review Committee of the University Medical Center Groningen (UMCG) determined that the Medical Research Involving Human Subjects Act (WMO) did not apply to this study.

Informed consent Written informed consent was obtained from the parents and children ≥ 12 years.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34. https://doi.org/10.3322/caac.21551
2. Johnston DL, Hyslop S, Tomlinson D, Baggott C, Gibson P, Orsey A, Dix D, Price V, Vanan M, Portwine C, Kuczynski S, Spiegler B, Tomlinson GA, Dupuis LL, Sung L (2018) Describing symptoms using the symptom screening in pediatrics tool in hospitalized children with cancer and hematopoietic stem cell transplant recipients. Cancer Med 7(5):1750–1755. https://doi.org/10.1002/cam4.1433
3. Dupuis LL, Lu X, Mitchell HR, Sung L, Devidas M, Mattano LA Jr, Carroll WL, Winick N, Hunger SP, Maloney KW, Kadan-Lottick NS (2016) Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: a prospective, longitudinal study from the children’s oncology group. Cancer 122(7):1116–1125. https://doi.org/10.1002/cncr.29876
4. Davidson HI, Pattison RM, Richardson RA (1998) Clinical undernutrition states and their influence on taste. Proc Nutr Soc 57(4): 633–638. https://doi.org/10.1079/pns19980092
5. Loeffen EA, Brinkema A, Medema KG, de Bock GH, Tissing WJ (2015) Clinical implications of malnutrition in childhood cancer patients—infections and mortality. Support Care Cancer 23(1):143–150. https://doi.org/10.1007/s00520-014-2350-9
6. Brinkema A, Sanderman R, Rooobol PF, Sulkers E, Burgerhof JG, de Bont ES, Tissing WJ (2015) Malnutrition is associated with worse health-related quality of life in children with cancer. Support Care Cancer 23(10):3043–3052. https://doi.org/10.1007/s00520-015-2674-0
7. Skolin I, Wahlin YB, Broman DA, Koivistio Hursti UK, Vikström Larsson M, Hernell O (2006) Altered food intake and taste perception in children with cancer after start of chemotherapy: perspectives of children, parents and nurses. Support Care Cancer 14(4):369–378. https://doi.org/10.1007/s00520-005-0904-6
8. Loves R, Plenert E, Tomlinson V, Palmert S, Green G, Schechter T, Tomlinson D, Vettese E, Zapance S, Dupuis LL, Sung L (2019) Changes in taste among pediatric patients with cancer and hematopoietic stem cell transplantation recipients. Qual Life Res 28:2941–2949. https://doi.org/10.1007/s11136-019-02242-5
9. Steinbach S, Hummel T, Bohlner C, Berktold S, Hundt W, Kriner M, Heinrich P, Sommer H, Hanusch C, Prechtl A, Schmidt B, Bauerfeind I, Seck K, Jacobs VR, Schmalfeldt B, Harbeck N (2009) Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol 27(11):1899–1905. https://doi.org/10.1200/jco.2008.19.2690
10. Cohen J, Laing DG, Wilkes FJ (2012) Taste and smell function in pediatric blood and marrow transplant patients. Support Care Cancer 20(11):3019–3023. https://doi.org/10.1007/s00520-012-1559-8
11. Comeau TB, Epstein JB, Migas C (2001) Taste and smell dysfunction in patients receiving chemotherapy: a review of current knowledge. Support Care Cancer 9(8):575–580.

12. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G (1997) Sniffin' sticks: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 22(1):39–52. https://doi.org/10.1093/chemse/b22.1.39

13. Croy I, Lange K, Krone F, Ngoeas S, Seo HS, Hummel T (2009) Comparison between odor thresholds for phenyl ethyl alcohol and butanol. Chem Senses 34(6):523–527. https://doi.org/10.1093/chemse/bjp029

14. Mueller C, Kallert S, Renner B, Stiassny K, Temmel AF, Hummel T, Kobal G (2003) Quantitative assessment of gustatory function in a clinical context using impregnated "taste strips". Rhinology 41(1):2–6

15. Miller U. Reedy FE (1990) Quantification of fungiform papillae and taste pores in living human subjects. Chem Senses 15(3):281–294

16. Shahbakeh M, Hutchinson I, Laing DG, Jinks AL (2005) Rapid quantitative assessment of fungiform papillae density in the human tongue. Brain Res 1052(2):196–201. https://doi.org/10.1016/j.brainres.2005.06.031

17. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9(7):676–682. https://doi.org/10.1038/nmeth.1919

18. Nuesse TM, Gameau NL, Sloan MM, Santorico SA (2015) Denver papillae protocol for objective analysis of fungiform papillae. J Vis Exp 100:e52860. https://doi.org/10.3791/52860

19. Cris W, Napier-Phillips A (2001) Mealtime behaviors of young children: a comparison of normative and clinical data. J Dev Behav Pediatri 22(5):279–286

20. Dovey TM, Jordan C, Aldridge VK, Martin CI (2013) Screening for feeding disorders. Creating critical values using the behavioural pediatrics feeding assessment scale. Appetite 69:108–113. https://doi.org/10.1016/j.appet.2013.05.019

21. Kazak AE, Hocking MC, Ittenbach RF, Meadows AT, Hobbie W, DeRosa BW, Leahy A, Kersun L, Reilly A (2012) A revision of the intensity of treatment rating scale: classifying the intensity of pediatric cancer treatment. Pediatr Blood Cancer 59(6):275–286.

22. DeRosa BW, Leahey A, Kersun L, Reilly A (2012) A revision of the intensity of treatment rating scale: classifying the intensity of pediatric cancer treatment. Pediatr Blood Cancer 59(6):275–286.

23. Schierer VA, Mori E, Petters W, Boerner C, Smitka M, Hummel T (2014) The "Sniffin' Kids" test—a 14-item odor identification test for children. PLoS One 9(6):e101086. https://doi.org/10.1371/journal.pone.0101086

24. Schierer VA, Agosin E, Altundag A, Avni H, Cao Van H, Corrino C, de Los SG, Fishman G, Fragola C, Guarneros M, Gupta N, Hudson R, Kamel R, Knapaila A, Konstantinidis I, Landis BN, Larsson M, Lundstrom JN, Macchi A, Marino-Sanchez F, Martinez Novakova L, Mori E, Mullol J, Nord M, Parma V, Philpott C, Propst EJ, Rawan A, Sandell M, Sorokowska A, Sorokowska P, Sparing-Paschke LM, Stetzler C, Valder C, Vodicka J, Hummel T (2018) Development of an international odor identification test for children: the Universal Sniff Test. J Pediatr 198:265–272.e263. https://doi.org/10.1016/j.jpeds.2018.03.011

25. Hedner M, Larsson M, Arnold N, Zucco GM, Hummel T (2010) Cognitive factors in odor detection, odor discrimination, and odor identification tasks. J Clin Exp Neuropsychol 32(10):1062–1067. https://doi.org/10.1080/13803910103563070

26. Lortsch J, Reichmann H, Hummel T (2008) Different odor tests contribute differently to the evaluation of olfactory loss. Chem Senses 33(1):17–21. https://doi.org/10.1093/chemse/bjm058

27. Millsop JW, Fazel N (2016) Oral candidiasis. Clin Dermatol 34(4):487–494. https://doi.org/10.1016/j.clindermatol.2016.02.022

28. IJpma I, Renken RJ, Gietema JA, Slart RHJA, Mensink MGJ, Lefrandt JD, Ter Horst GJ, Reyners AKL (2017) Changes in taste and smell function, dietary intake, food preference, and body composition in testicular cancer patients treated with cisplatin-based chemotherapy. Clin Nutr (Edinb, Scotl) 36(6):1642–1648. https://doi.org/10.1016/j.clnu.2016.10.013

29. Wall DT, Gabriel LA (1983) Alterations of taste in children with leukemia. Cancer Nurs 6(6):447–452

30. Nolden AA, Hwang LD, Bolting A, Reed DR (2019) Chemosensory changes from cancer treatment and their effects on patients' food behavior: a scoping review. Nutrients 11(10). https://doi.org/10.3390/nu11102285

31. Hong JH, Omur-Ozbek P, Stanek BT, Dietrich AM, Duncan SE, Lee YW, Lesser G (2009) Taste and odor abnormalities in cancer patients. J Support Oncol 7(2):39–56

32. Gamper EM, Zabernigg A, Wintner LM, Giesinger JM, Oberguggenberger A, Kemmler G, Sperner-Unterweger B, Holzner B (2012) Coming to your senses: detecting taste and smell alterations in chemotherapy patients. A systematic review. J Pain Symptom Manag 44(6):880–895. https://doi.org/10.1016/j.jpainsymman.2011.11.011

33. Wang H, Zhou M, Brand J, Huang L (2009) Inflammation and taste disorders: mechanisms in taste buds. Ann N Y Acad Sci 1170:596–603. https://doi.org/10.1111/j.1749-6632.2009.04480.x

34. Ishinaga K, Higa M, Yasuda M, Kuswana M, Nishiwaki C, Sunaga M, Okamura H (2018) Alterations in emotional responses (pleasantness/unpleasantness) induced by sniffing food odors during chemotherapy in patients with lung cancer. Jpn J Clin Oncol 48(10):906–912. https://doi.org/10.1093/jjco/hyy123

35. Gibson F, Shipway L, Barry A, Taylor RM (2012) What's it like when you find eating difficult: children's and parents' experiences of food intake. Cancer Nurs 35(4):265–277. https://doi.org/10.1097/CCN.0b013e31822cd4d0

36. Drewnowski A (1997) Taste preferences and food intake. Annu Rev Nutr 17:237–253. https://doi.org/10.1146/annurev.nutr.17.1.237

37. Mattes RD, Cowart BJ, Schiavo MA, Arnold C, Garrison B, Kare MR, Lowry LD (1990) Dietary evaluation of patients with smell and/or taste disorders. Am J Clin Nutr 51(2):223–240. https://doi.org/10.1093/ajcn/51.2.233

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.